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Objective. In the K/BxN mouse model of rheu-
matoid arthritis, T cells reactive for the self antigen
glucose-6-phosphate isomerase (GPI) escape negative
selection even though GPI expression is ubiquitous. We
sought to determine whether insufficient GPI presenta-
tion could account for the failure of negative selection
and for the development of arthritis.
Methods. To increase the antigen presentation
of GPI, we generated transgenic mice expressing a
membrane-bound form of GPI (mGPI) and crossed
them with K/BxN mice. A monoclonal antibody specific
for the -chain of the KRN T cell receptor was gener-
ated to examine the fate of GPI-specific T cells.
Results. The mGPI-transgenic mice presented
GPI more efficiently and showed a dramatic increase in
negative selection and an inhibition of arthritis. Inter-
estingly, thymic negative selection remained incomplete
in these mice, and the escaped autoreactive T cells were
anergic in the peripheral lymphoid organs, suggesting
that enhanced antigen presentation also induces peri-
pheral tolerance. Despite this apparent tolerance induc-
tion toward GPI, these mice developed a chronic wasting
disease, characterized by colonic inflammation with
epithelial dysplasia, as well as a dramatic reduction in
Treg cells.
Conclusion. These data indicate that insufficient
autoantigen expression or presentation results in de-
fects of both central and peripheral tolerance in the
K/BxN mice. Our findings also support the idea that
insufficient autoantigen levels may underlie the devel-
opment of autoimmunity.
Negative selection requires that self antigens be
properly accessed and efficiently presented to develop-
ing thymocytes (1,2). Hence, the expression levels and
patterns of self antigens might affect the efficiency of
clonal deletion (3,4). The relationship between serum
protein levels and T cell clonal deletion has been
investigated in several experimental systems. A serum
concentration of hen egg lysozyme as low as 0.1 ng/ml
(1011M) is sufficient to delete 3A9, but not 3.L2, hen
egg lysozyme–specific T cells (5). In contrast, deletion of
T cells specific for an Ig light chain as self antigen
requires a serum concentration of 100 g/ml (106M)
(6). Thus, the minimum expression level of a self antigen
required for efficient negative selection varies greatly
depending on the antigen and T cell receptor (TCR),
most likely reflecting inherent differences in the way
these self antigens gain access to the thymus and are
processed by thymic antigen-presenting cells (APCs),
as well as the affinity of the resulting peptide for major
histocompatibility complex (MHC) molecules and the
affinity of those peptide–MHC complexes for their cog-
nate TCRs.
While these studies suggest a link between ex-
pression levels and tolerance induction, it is not well
understood whether insufficient self-antigen expression
and presentation contribute to defective T cell tolerance
and development of autoimmunity. Lower susceptibility
to type 1 diabetes mellitus in humans is associated with
higher expression levels of insulin in the thymus, sug-
gesting that higher levels of insulin in the thymus might
promote negative selection of insulin-specific T cells (7).
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Consistent with this idea, transgenic overexpression of
preproinsulin 2 was shown to substantially reduce the
onset and severity of type 1 diabetes mellitus in non-
obese diabetic mice (8).
To explore how insufficient self-antigen presen-
tation underlies defective central tolerance and, in turn,
the development of autoimmunity, we used the K/BxN
mouse model of rheumatoid arthritis caused by defective
tolerance of a self-reactive transgenic TCR. K/BxN mice
are generated when KRN TCR–transgenic mice on
the B6 background (K/B) are crossed with NOD strain
mice (9). The KRN TCR specifically recognizes a pep-
tide of glucose-6-phosphate isomerase (GPI) presented
by the NOD mouse–derived class II MHC Ag7 molecule.
Young K/BxN mice show signs of clonal deletion in the
thymus; however, significant numbers of mature CD4
T cells are observed at 3–4 weeks of age (9). Escaped
KRN T cells become activated and drive B cells to
produce high titers of anti-GPI antibodies, which induce
arthritis in the joint by activating the complement cas-
cade and cells of the innate immune system (10).
GPI is a ubiquitous enzyme involved in the
glycolytic pathway. An important question is how KRN
T cells that recognize a ubiquitous protein escape the
series of elaborate mechanisms that usually ensure tol-
erance to self antigens. Peptides eluted from I-Ag7 on
B cells include peptides from GPI (11,12); however,
the specific GPI peptide that is recognized by the KRN
TCR, GPI282–294, is not among them, suggesting that
GPI is not efficiently processed and presented to KRN
T cells. In an earlier study, transgenic expression of
G7m, a peptide mimic of GPI282–294, showed massive
thymic deletion of KRN T cells and elimination of
Treg cells, but the precise fate of KRN T cells could not
be tracked due to the lack of a clonotype antibody (13).
Additionally, the G7m mimotope stimulates KRN
T cells in vitro 10–100-fold better than the endogenous
GPI282–294 peptide. While the mimotope seems to de-
rive most of this enhancement from increased binding
to MHC molecules, some of the TCR contact residues
differ from the native GPI peptide, which could pos-
sibly affect TCR avidity for the altered peptide–MHC
complex.
In this study, we tested the hypothesis that insuf-
ficient processing and presentation of GPI could ac-
count for the failure of negative selection and tolerance
in the K/BxN mice by increasing the antigen presenta-
tion of endogenous GPI. We generated a transgenic
mouse expressing a membrane-bound form of GPI
(mGPI) and a KRN TCR -chain–specific antibody to
track transgenic T cells. We showed that the presence of
the mGPI transgene resulted in more efficient presen-
tation of the GPI peptide, extensive deletion of KRN
T cells in the thymus, and inhibition of the development
of arthritis. Despite this greatly enhanced negative se-
lection, KRN T cells still escape and accumulate in the
periphery, yet unlike their arthritogenic counterparts,
these escaped T cells are maintained in an unrespon-
sive state towards GPI. This unresponsiveness does not
appear to be mediated by Treg cells, as mGPI-transgenic
mice develop much fewer thymic and splenic Treg cells
compared to their non-transgenic littermates. Further-
more, this decrease in Treg cells correlates with the
development of a wasting disease characterized by co-
lonic inflammation and high-grade epithelial dysplasia.
Taken together, our data indicate that insufficient auto-
antigen expression and presentation can affect both
central and peripheral tolerance and may underlie the
development of autoimmunity.
MATERIALS AND METHODS
Generation of mGPI-transgenic mice. The leader se-
quence from the H-2Kb gene was amplified by polymerase
chain reaction (PCR) from the pODpCAGGS plasmid (14)
and ligated to the full-length complementary DNA (cDNA) of
GPI. The joint fragment was cloned into the pODpCAGGS
plasmid using Xba I to fuse to the H-2Db transmembrane
region. The fragment without vector sequences was used to
generate transgenic B6 mice by staff at the Transgenic Core
Facility of the University of Chicago. Founders were identified
by PCR of tail DNA using specific primers. All experiments
were approved by the Institutional Animal Care and Use
Committee of the University of Chicago.
Western blotting. Organs were homogenized in a tissue
grinder with glass pestles (Kontes Glass) in 50 mM Tris HCl,
pH 7.4, 150 mM NaCl, and 1% Nonidet P40 with a protease
inhibitor cocktail (Roche). The lysates were centrifuged at
12,000g. The supernatant was used for the cytoplasmic frac-
tion. The pellet (including nuclei) was dissolved in 2% sodium
dodecyl sulfate, sonicated, and used for the membrane frac-
tion. GPI was detected using serum from the K/BxN mice.
The blots were stripped and reprobed with an anticlathrin
heavy-chain antibody (clone 23, catalog no. 610500; BD Trans-
duction Laboratory) and an antiactin antibody (catalog no.
MAB1501R; Chemicon) for the membrane and cytoplasmic
fractions, respectively.
Quantitative reverse transcription–PCR (RT-PCR).
Organs were homogenized in TRIzol using a Dounce homog-
enizer. Following RNA purification, 1 g of total RNA was
used for cDNA synthesis by SmartScribe reverse transcriptase
(Clontech).
Forward (CCACTAACGGACTGATCAGCTTCATC)
and reverse (AAGAGTCAGTGGACGGAGGA) primers
were designed to specifically amplify the mGPI transgene, and
quantitative RT-PCR was performed using SYBR Green PCR
Master Mix (Applied Biosystems). Ct values were normalized
2848 PERERA ET AL
to a standard curve of cDNA from an mGPI transgene–
positive colon sample.
Enzyme-linked immunosorbent assay (ELISA). Serum
titers of IgG anti-GPI were determined by ELISA. Plates were
coated with 5 g/ml of recombinant mouse GPI. Serial dilu-
tions of serum samples were detected with the use of biotin-
ylated goat anti-mouse IgG (subclasses 1 plus 2a plus 2b plus 3)
Fc-specific antibody (Jackson ImmunoResearch) followed by
alkaline phosphatase–conjugated streptavidin. The data were
fitted by a 4-parameter curve using GraphPad Prism software.
The titer was defined as the serum dilution that gave an optical
density of 50% maximum (inflection point) of the curve.
T cell hybridoma and antigen presentation assay.
Naive T cells from KRN-transgenic mice on the B6 back-
ground were injected into TCR–/–/B6xNOD F1 mice to
activate them. One week after injection, CD4 T cell were
purified from the host spleen and were directly fused with the
BWZ.36 fusion partner (15). T cell hybrids were subcloned and
screened for LacZ activity after culturing with GPI-specific
B cells as APCs. Clone G2 was chosen for its high LacZ activity
and low background activity.
For antigen presentation assays, 1  105 KRN.G2
hybridoma cells were incubated for 24 hours in 96-well plates
with splenocytes from the indicated mice. Cells were lysed, and
the total LacZ activity was measured using chlorophenol red
-D-galactopyranoside, a chromogenic substrate.
Primary T cell proliferation assay. Splenocytes were
labeled with carboxyfluorescein succinimidyl ester (CFSE) and
enriched for CD4 cells by positive selection on magnetic
columns. Labeled CD4 splenocytes (2.5  104) were mixed
with stimulator splenocytes from a B6xNOD F1 mouse (2.5 
105) that had been depleted of CD4 and CD8 cells by
negative selection on magnetic columns. Cells were cultured in
complete medium for 4.5 days with graded concentrations of
GPI282–294 peptide, with or without of 25 units/ml of human
interleukin-2 (IL-2; PeproTech). Cells were stained with anti-
CD4, anti-KRN, and propidium iodide and analyzed on a
FACSCanto analyzer (BD Biosciences).
Antibodies and flow cytometry. Anti-KRN antibody
(clone 3-4G-B7) was generated by immunizing B6 mice with
KRN T cells that also express a membrane-bound ovalbumin
as carrier for T cell help (14) (details to be described in a
separate article at a later date). Commercially obtained mono-
clonal antibodies used in these studies included anti-CD4,
anti-CD8, anti-TCR V6, and anti-TCR (BD PharMingen).
Detection of Treg cells was carried out with a FoxP3 stain-
ing kit (eBioscience). Briefly, cells were first stained with
anti-CD4, anti-CD8, or anti-CD25 antibodies and were then
stained intracellularly with anti-FoxP3.
Generation of bone marrow chimeric mice. T cell–
depleted bone marrow cells (1–5  106) were administered to
lethally irradiated (1,050 rads) host mice by intravenous injec-
tion through the tail vein. Chimeric mice were analyzed 2–3
months after the bone marrow reconstitution.
RESULTS
Generation of mGPI-transgenic mice. Mem-
brane proteins are processed and presented efficiently
by class II MHC molecules, and expression of peptide in
a membrane-bound form enhances its presentation
(16,17). Therefore, we adapted the approach of Ehst
et al (14) to express a membrane-bound form of GPI by
fusing a signal peptide to the N-terminus of GPI and a
membrane domain to its C-terminus. The fusion protein
is driven by a ubiquitous chicken -actin promoter and a
cytomegalovirus immediate-early enhancer (Figure 1A).
Since GPI is an enzyme involved in glucose
metabolism and its overexpression might have adverse
effects, we mutated the histidine-388, which is critical
for its enzymatic activity (18), to a glycine. This muta-
tion does not change the GPI peptide 282–294 that is
recognized by KRN T cells. The expression of the con-
struct was first tested in cultured 293 cells. As shown in
Figure 1B, surface GPI expression was readily detect-
able by flow cytometry.
The construct was then used to generate trans-
genic mice on the C57BL/6 background, and 11 founders
were identified by PCR. Unexpectedly, we were not able
to detect surface GPI expression in any of the founders.
The lack of surface GPI expression could be due to
incorrect folding, unstable configuration on the cell sur-
face, or its quick internalization. However, surface ex-
pression is not required for efficient antigen processing
and presentation (16), and expression of mGPI did
target GPI to the membrane fraction of cells without
affecting the endogenous, cytoplasmic GPI levels, as
demonstrated by Western blot analysis (Figure 1C). One
transgenic mouse line (line 5, designated as mGPI) was
used in subsequent studies. Using quantitative RT-PCR,
we confirmed that transgene expression in this line was
detectable in all organs assayed (Figure 1E).
Increased presentation of GPI peptide in mGPI-
transgenic mice. To confirm that overexpression of
mGPI increased the presentation of GPI peptide, we
generated a T cell hybridoma (designated KRN.G2)
using T cells from KRN-transgenic mice and BWZ.36
fusion partner that carries an NF-AT-LacZ construct
(15). Upon TCR engagement by the cognate peptide–
MHC complex, LacZ is produced, providing a conve-
nient and sensitive readout relative to the measurements
of IL-2 production. The mGPI mice were first bred to
the B6.H-2g7 congenic mice to introduce the I-Ag7
molecule (referred to as mGPI/g7 mice), since KRN T
cells are specific for GPI peptide presented by I-Ag7
only. KRN.G2 hybridoma cells were cultured with
splenocytes from mGPI/g7 mice or transgene-negative
littermates (mGPI/g7), or as a positive control, the cells
were cultured with splenocytes from the anti-GPI Ig-
knockin mice on a Rag/mouse background, since they
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have a homogeneous population of GPI-specific B cells
(19). The minimum number of mGPI/g7 splenocytes
needed to induce LacZ was found to be 10–50-fold less
than the minimum number of mGPI/g7 splenocytes
needed, which verified the enhanced presentation of
GPI peptide in mGPI/g7-transgenic mice (Figure 1D).
Inhibition of arthritis development by mGPI. We
next crossed the mGPI/g7 mice with the KRN TCR–
transgenic mice to test how arthritis development was
affected by the enhanced GPI presentation. The re-
sulting mGPI/K/g7 mice and mGPI/K/g7 littermate
controls were monitored for the onset and severity of
arthritis after they were weaned. As described previously
(9), mGPI/K/g7 mice developed arthritis between 4
weeks and 5 weeks of age, with a sharp onset of joint
swelling. Maximum ankle swelling was reached at 6–8
weeks of age, which was followed by ankle deformity.
In contrast, 85% of the mGPI/K/g7 mice had no sign
of arthritis. The remaining 15% of the mGPI/K/g7
mice developed mild arthritis with a delayed onset
(Figure 2A).
Since arthritis is mediated by pathogenic anti-
GPI antibodies, we determined the serum anti-GPI IgG
antibody titers in both groups of mice. As shown in
Figure 2B, the levels of IgG anti-GPI antibodies in the
mGPI/K/g7 mice were 1,000-fold lower than those in
the mGPI/K/g7 mice. Thus, the blocked arthritis devel-
opment in the mGPI/K/g7 mice occurs before the
production of anti-GPI antibodies.
Negative selection of KRN T cells in mGPI-
transgenic mice. The prevention of autoantibody pro-
duction and arthritis in mGPI/K/g7 mice indicated
that tolerance to GPI was restored. We analyzed the
T cell compartments of these mice by flow cytometry. As
described previously (9), negative selection of KRN
T cells in K/BxN mice was inefficient, and significant
populations of mature single-positive cells are present in
the thymus and peripheral lymphoid organs. In contrast,
Figure 1. Generation of a membrane-bound glucose-6-phosphate isomerase (mGPI)–transgenic mouse. A, Map of the mGPI construct used to
generate transgenic mice. B, Expression of mGPI on 293 cells that had been transiently transfected with the mGPI construct (solid line) by staining
with an anti-GPI monoclonal antibody, as compared to mock-transfected control cells (dotted line). C, Subcellular distribution of mGPI. Cytoplasmic
and membrane fractions from the spleen and thymus of mGPI/g7 and mGPI/g7 mice were analyzed by Western blotting. Anticlathrin heavy chain
(HC) antibodies and anti–-actin antibodies were used as loading controls for membrane and cytoplasmic fractions, respectively. The calculated
molecular weights of endogenous GPI and mGPI are 62.8 kd and 67.6 kd, respectively. D, Capacity of splenocytes from mGPI/g7 mice to present
GPI peptide. KRN.G2 hybridoma cells (1  105) were incubated with splenocytes from mGPI/Ag7 mice, mGPI/Ag7 mice, and anti-GPI B cell
receptor (BCR)–knockin mice. Total LacZ activity was measured using the chromogenic substrate chlorophenol red -D-galactopyranoside. LacZ
activities were normalized to an internal control. Values are the mean  SD of 3 independent experiments. E, Detection of mGPI transcript in the
spleen, thymus, and colon. Real-time polymerase chain reaction analysis was performed using transgene-specific primers, and the Ct values were
normalized to a standard curve of mGPI/g7 mouse colon cDNA. Each data point represents a single mouse; horizontal lines show the mean.
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thymocyte deletion in mGPI/K/g7 mice was much more
effective, with a 6-fold reduction in total cellularity
(Figure 3B). Analysis of the CD4/CD8 compartments
showed an almost complete deletion of the double-
positive (DP) thymocytes with relatively little change to
the double-negative (DN) compartment, which resulted
in a dramatic decrease in the ratio of DP to DN cells
(Figures 3A and B). The total number of CD4 single-
positive thymocytes was decreased by 2-fold, although
the percentage was increased. Despite the efficient
deletion of thymocytes, there was no dramatic difference
in the total number of splenocytes (mean  SD 1.48 
0.5  108 in mGPI–/K/g7 mice and 1.75  0.7  108 in
mGPI/K/g7 mice) and the percentage of CD4 T cells
(Figure 3A). Analysis of activation markers on CD4
T cells from both mouse groups showed an increased
proportion of CD44highCD62low cells, consistent with
previous antigen encounter (data not shown). The in-
creased negative selection phenotype is not dependent
on the age of the animals, as mice analyzed at 2 weeks of
age showed very similar results (Figure 3C).
Since allelic exclusion for the TCR chain is not
very efficient in T cells, it was not clear whether the
escaping CD4 T cells still expressed the transgene-
encoded receptor or whether they instead expressed re-
ceptors produced through endogenous rearrangements.
To distinguish these possibilities, we generated an anti-
body (clone 3-4G-B7) specific for the -chain of the
KRN TCR (Perera J, et al: unpublished data) and used
it to track the fate of KRN-expressing T cells, since all of
the cells that express the KRN -chain also express the
KRN -chain. As shown in Figure 3D, 3-4G-B7 was
specific for KRN T cells and showed no staining of
wild-type T cells. The percentage of KRN T cells in
the CD4 single-positive compartment in the thymus was
reduced slightly, but the number of KRN T cells was
reduced by 3-fold, confirming the increased deletion of
KRN T cells (Figures 3C and D). Similar changes
were seen in the periphery, where the percentage of
Figure 2. Effect of membrane-bound glucose-6-phosphate isomerase
(mGPI) transgene on arthritis development. A, Ankle thickness in
mGPI/K/g7 mice (circles) and in mGPI/K/g7 littermate controls
(squares). Monitoring started at 3 weeks of age. Values are the
mean  SD of 35 mGPI/K/g7 mice and 37 for mGPI/K/g7 mice. B,
Serum titers of IgG anti-GPI in 8–12-week-old mGPI/K/g7 and
mGPI/K/g7 mice. Each data point represents a single mouse; hori-
zontal lines show the mean. Differences between groups were signifi-
cant (P  0.001 for each comparison, by Student’s unpaired t-test).
Figure 3. Selection of KRN T cells and usage of transgene-encoded T
cell receptor (TCR) chains. A, Flow cytometry of cells prepared from
the thymus or spleen of mGPI/K/g7-transgenic mice and mGPI/
K/g7 littermate controls at 8–12 weeks of age. Cells were stained with
anti-CD4 and anti-CD8 antibodies. Numbers represent the percentage
of cells within the gate for the sample shown. B, Ratio of double-
positive (DP) cells to double-negative (DN) cells in the thymus (top)
and the number of total thymocytes (bottom) in 8–12-week-old mice
(n  5 per group and n  8 per group, respectively). C, Ratio of DP
cells to DN cells in the thymus (top) and the number of total
thymocytes (bottom) in 2-week-old mice (n  6 per group). D, Cells
prepared from the thymus and spleen of B6xNOD F1 (BxN), mGPI/
K/g7 control, and mGPI/K/g7-transgenic mice at 8–12 weeks of age.
Cells were stained with an antibody specific for KRN TCR (3-4G-B7)
and analyzed by flow cytometry, gating first on CD4 single-positive
cells. Numbers represent the mean SD percentage of cells within the
KRN gate for 5 mice. E, Total number of CD4 single-positive
KRN T cells in the thymus (top) and spleen (bottom) of mGPI/
K/g7 and mGPI/K/g7 mice (n  5 per group). Values in B, C, and E
are the mean  SD.   P  0.05;   P  0.01;   P  0.001,
by Student’s unpaired t-test.
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KRN T cells among CD4 T cells was decreased 40%,
and the number of KRN T cells was reduced 3-fold
(Figures 3D and E). These results show that despite a
reduction in numbers, there is still a significant popula-
tion of KRN T cells in the periphery, however, the
abrogation of antibody production and arthritis indicate
that these KRN T cells are functionally silenced.
We confirmed this by measuring the T cell re-
sponse to GPI282–294 peptide in vitro. CD4 T cells from
the spleens of mGPI/K/g7 and mGPI/K/g7 mice were
enriched and labeled with CFSE. These labeled spleno-
cytes were mixed with Ag7-bearing stimulator cells in the
presence of graded amounts of GPI282–294 peptide.
KRNCD4 T cells from mGPI/K/g7 mice prolifer-
ated robustly in response to peptide, while T cells from
mGPI/K/g7 mice did not (Figures 4A and B). In cer-
tain models of T cell anergy, the addition of exogenous
IL-2 can restore proliferation (20); however, we did not
observe any effect on KRN T cells in cultures of cells
derived from mGPI/K/g7 mice and supplemented
with IL-2 (Figure 4B). These data support the idea that
the escaped KRN T cells are maintained in a state of
tolerance to GPI in the peripheral immune system.
Contribution of bone marrow–derived versus
non–bone marrow–derived APCs. Thymic APCs can be
subdivided into radiosensitive bone marrow–derived he-
matopoietic cells and radioresistant non–bone marrow–
derived thymic epithelial cells. Both types of cells can
efficiently mediate negative selection if they have access
to the antigens (21). Since the mGPI transgene was driven
by a ubiquitous promoter, we compared the relative
contribution of bone marrow–derived APCs versus thy-
mic epithelial cells for the efficient clonal deletion of the
KRN T cells observed in the transgenic mGPI/K/g7
mice. Four types of bone marrow–chimeric mice were
generated using bone marrow donors or hosts that did or
did not express the mGPI transgene (Figure 5). Chimera
4 served as the negative control, since neither the bone
marrow donor nor the host carried the mGPI transgene.
Chimera 1 served as the positive control since both the
bone marrow donor and the host carried the mGPI
transgene. In chimera 2, only the bone marrow donor
carried the mGPI transgene, and in chimera 3, only the
host carried the mGPI transgene.
Analyses of the numbers of total thymocytes and
the ratio of DP cells to DN cells showed that either
bone marrow–derived APCs or thymic epithelial cells
could mediate the efficient deletion of KRN T cells;
however, thymic epithelial cells were slightly more effi-
cient than bone marrow–derived APCs (by comparing
chimera 2 and 3). Thymic epithelial cells also induced a
more dramatic reduction in the DP:DN cell ratio, sug-
gesting that the deletion takes place at an earlier stage
in thymocyte development. This is consistent with the
different anatomic localization of developing thymo-
cytes. DP cells are mostly localized in the cortex, and
they will be deleted by cortical thymic epithelial cells
that have a sufficient amount of peptide–MHC complex.
Deletion by bone marrow–derived APCs that mainly
reside in the thymic medulla will occur at a later stage in
development.
Defective Treg cell production and development
of wasting disease in mGPI/K/g7 mice. Although
mGPI/K/g7 mice did not develop arthritis, measure-
Figure 4. T cell proliferation in response to the 282–294 peptide of
glucose-6-phosphate isomerase (GPI). CD4 T cells (2.5  104) from
mGPI/K/Ag7 and mGPI/K/Ag7 mice (2–5 months of age) were
labeled with carboxyfluorescein succinimidyl ester (CFSE) and cocul-
tured for 4.5 days in 96-well plates with Ag7-bearing stimulator cells
(2.5  105) in the presence of graded amounts (M) of GPI282–294
peptide and 25 units/ml of interleukin-2 (IL-2). Individual cultures
were analyzed by flow cytometry after staining with anti-CD4 and
anti–KRN T cell receptor -chain (TCR) antibody. A, Representa-
tive flow cytometry plots of T cell proliferation in response to the
GPI282–294 peptide. Numbers represent the percentage of T cells that
are KRN and have diluted CFSE (left) or remain undivided (right).
B, Quantification of T cell proliferation relative to that in unstimulated
controls. Data are shown as the fold change in the total number of
KRN T cells in culture at the end of 4.5 days relative to the total
number in unstimulated controls. Results are representative of 3
independent experiments. Values are the mean  SD of triplicate
wells.
2852 PERERA ET AL
ment of their body weight over time showed that their
growth was arrested early (Figure 6B). By 2–3 months of
age, they started to exhibit hunched posture, had ruffled
fur, and were thin and lethargic. The mice that devel-
oped the most severe phenotypes were euthanized ac-
cording to the guidelines of the Institutional Animal
Care and Use Committee. The survival of the mice
decreased with age, and by 5 months of age, only 35% of
mice had survived (Figure 6A). A survey of multiple
organs from these mice did not show overt inflammation
in the liver, kidney, lung, heart, or pancreas. Analysis of
the gastrointestinal tract of these animals revealed that
the small intestine was histologically normal, but the
large intestine (cecum and colon) demonstrated mild-
to-severe, active, chronic inflammation in 90% of
the mice analyzed at 2–5 months of age (Figure 6D). In
5 of 11 mice, low-grade epithelial dysplasia was ob-
served, and in another mouse, high-grade dysplasia
Figure 6. Wasting phenotype and loss of Treg cells in mGPI/K/g7-
transgenic mice. A, Survival curves for mGPI/K/g7 mice (n  31) as
compared with mGPI/K/g7 mice (n  15). Marks on the curve indicate
when individual mice were removed. B, Changes in body weight of the
mGPI/K/g7, mGPI/K/g7, and mGPI/K/b mice over time. Values are
the mean  SD of 35, 21, and 14 mice per group, respectively. C, Colon
section from an mGPI/K/g7 control mouse showing normal histologic
features. D, Colon section from an mGPI/K/g7 mouse showing active
and chronic inflammation, with architectural distortion of crypts. Bars 
0.1 mm. E, Detection of Treg cells in the thymus and spleen of 8–12-
week-old mGPI/K/g7 and mGPI/K/g7 mice by flow cytometry. Values
are the mean  SD percentage of Treg cells (n  15 mice per group). F,
Total number of FoxP3CD25 cells in the thymus (top) and spleen
(bottom). Values are the mean  SD of 15 mice per group. Differences
between groups were significant (P  0.001 for each comparison, by
Student’s unpaired t-test). G, Percentages of KRN-transgenic mouse T
cells within the FoxP3 Treg cell compartment, as determined with the
anti-KRN chain antibody. Values are the mean  SD of 3 mice per
group. H, Proliferation of KRN T cells from mesenteric lymph nodes
(MLNs) and spleen in response to GPI282–294 peptide at 6 months of age.
Data are shown as the fold change in the total number of KRN T cells in
culture at the end of 4.5 days relative to the total number in unstimulated
controls. Results are representative of 3 independent experiments. Values
are the mean  SD of triplicate wells.
Figure 5. Contribution of bone marrow (BM)–derived antigen-
presenting cells (APCs) versus non–bone marrow–derived APCs in the
deletion of KRN T cells. Crisscross bone marrow chimeric mice were
generated by using bone marrow donors and hosts that did () or did
not () carry the membrane-bound glucose-6-phosphate isomerase
transgene. Hosts were lethally irradiated (1,050 rads) before bone
marrow reconstitution, and the mice were evaluated 3 months later.
The numbers of total thymocytes (top) and the ratio of double-positive
(DP) to double-negative (DN) cells in the thymus (bottom) are shown
for each combination of bone marrow donor and host. Values are the
mean  SD of 6–12 mice per group.   P  0.004;   P  0.0001,
by Student’s unpaired t-test. NS  not significant.
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with invasion into the submucosal lining (data not
shown) was noted. In contrast, we observed no colonic
inflammation or dysplasia in mGPI transgene–negative
mice (Figure 6C).
We next examined whether Treg cells were af-
fected in mGPI/K/g7 mice. As shown in Figure 6E, the
percentages of FoxP3CD25 Treg cells were greatly
reduced in the thymus and spleen of mGPI/K/g7 mice.
The absolute numbers of Treg cells were decreased
13.8-fold in the thymus and 3.8-fold in the spleen (Figure
6F). This reduction was not due to an inability of KRN
T cells to be recruited into the Treg cell compartment, as
KRN Treg cells are observed at similar frequencies in
both genotypes (Figure 6G). Consistent with the role of
Treg cells in suppressing intestinal autoimmunity in
many experimental models (22), these data suggested
that loss of Treg cells might be responsible for the
development of colitis and wasting in the mGPI/K/g7
mice.
Given the unresponsive nature of KRN T cells
in the spleen of mGPI/K/g7 mice, we sought to deter-
mine whether KRN T cells were anergic in the gut. We
measured the ability of mGPI/K/g7 T cells from the
mesenteric lymph nodes of 6-month-old mice to respond
to GPI282–294 peptide stimulation in vitro. While KRN
T cells from the mesenteric lymph nodes of mGPI/K/g7
mice expanded dramatically relative to their splenic
counterparts, those from mGPI/K/g7 mice remained
unresponsive to peptide (Figure 6H).
DISCUSSION
In this study, we investigated whether insuffici-
ent presentation of self antigens could account for the
escape of autoreactive cells from negative selection and
the breakdown of tolerance in the case of a ubiquitous
self antigen. In this study, we showed that enhanced
presentation of GPI indeed dramatically increased KRN
T cell deletion at the double-positive stage in the thymus
and prevented the development of arthritis. The mas-
sive deletion in the thymus was also accompanied by
significant loss of regulatory T cells and severe chronic
inflammation in the colon of these transgenic animals.
Biochemical, structural, and functional analyses
of the class II MHC I-Ag7 molecule suggest that its
peptide-binding properties play important roles in auto-
immunity (23). In particular, I-Ag7 binds to many of its
ligands in the low micromolar range, which is weak as
compared to other murine alleles, such as I-Ak, that bind
to their peptides in the nanomolar range. The escape of
autoreactive T cells specific for the insulin -chain
peptide (9–23) is attributed to the weak binding of the
peptide to the I-Ag7 molecule (for review, see ref. 23).
Comparison of the core GPI peptide (SIALHVGFD) to
the I-Ag7 peptide binding motif (24) shows the presence
of preferred amino acids at multiple positions. However,
the inability to detect this peptide among those eluted
from I-Ag7 on B cells, which include other GPI peptides,
supports a model in which weak binding of GPI282–294
to I-Ag7 allows for the escape of KRN T cells (11,12).
Our results show that higher expression levels may
compensate for the lower affinity of peptide for the
MHC. Therefore, the efficiency of tolerance induction
of a particular T cell specificity may depend on multiple
factors, including the expression level of self protein, the
efficiency of antigen processing and presentation, and
the affinity of peptide for the MHC.
Self-antigen expression levels can affect Treg cell
differentiation, although the mechanism is not well
understood (for review, see refs. 25 and 26). In mGPI/
K/g7 mice, increased antigen presentation leads to de-
creased number of Treg cells. Our results are consistent
with those of previous studies in which TCR-transgenic
mice specific for hemagglutinin (HA) were crossed with
multiple lines of mice expressing different levels of HA
(25). It was shown that the differentiation of Treg cells is
dependent on the recognition of self peptide (HA
peptide), since few Treg cells developed in mice express-
ing just the TCR transgene. Higher levels of HA expres-
sion led to more efficient deletion of cognate T cells. Of
the cells that evaded deletion, similar proportions ac-
quired FoxP3 expression. The net result was that higher
expression levels of HA led to lower total numbers of
Treg cells.
While the mechanism for the development of
colitis in the mGPI/K/g7 mice was not addressed
herein, our results are consistent with the well-
established role of regulatory T cells in maintaining
intestinal homeostasis (for review, see ref. 22). In the
T cell–transfer model of colitis, adoptively transferred
naive CD4 T cells cause intestinal inflammation in
recipient SCID mice, and colitis can be prevented by
cotransferred Treg cells. The colitis in mGPI/K/g7 mice
could be attributed to a decrease in Treg cell production,
along with a potential narrowing of Treg cell specificities
due to expression of the TCR transgene. It is also
possible that KRN T cells and mGPI expression in the
colon play a role in the pathogenesis of colitis. It has
been demonstrated that colonic epithelial cells can
aberrantly express class II MHC molecules in response
to inflammation (27). The high expression of the mGPI
transgene in the colon might contribute to the presen-
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tation of GPI to the KRN T cells by colonic epithelial
cells or other APCs, thereby exacerbating disease.
Our data support the idea that the mechanisms of
both central and peripheral tolerance are important to
the prevention of autoimmunity. It has been estimated
that one-half to two-thirds of thymocytes that are posi-
tively selected subsequently undergo negative selection
(for review, see ref. 28). However, central tolerance is
neither perfect nor foolproof. In our model, there are
plenty of KRN T cells in the peripheral immune system
of mGPI/K/g7 mice, yet they do not initiate disease.
How are they functionally silenced? Since the Treg cell
numbers are significantly reduced in the mGPI/K/g7
mice, Treg cells do not appear to be responsible for
the reinstatement of tolerance. Anergy is one of the
major mechanisms of peripheral tolerance, and in vivo
anergy has been described for several transgenic TCRs
(for review, see ref. 29). Our system resembles those
models in terms of the unresponsiveness of T cells and
the inability of exogenous IL-2 to rescue proliferation.
Studies looking at the effect of antigen expression level
on in vivo anergy induction found that a pigeon cyto-
chrome c transgene was capable of tolerizing transgenic
T cells equally well at both high and low expression
levels (30).
Our model is unique in two respects. First, in our
model, the natural level of presentation leads to activa-
tion, and only high levels of antigen presentation lead
to tolerance. Second, arthritis development provides a
functional in vivo readout for T cell fate decision. It is
possible that in our system, mGPI expression affects not
only the strength of antigenic stimulation, but also the
major type of APCs involved. In mGPI/K/g7 mice, the
capacity of all B cells to present GPI is increased. It
has been shown that targeting antigens to B cells could
induce T cell tolerance (31–33). Further mechanistic
studies are needed, and the results could shed light on
the ways that autoreactive T cells escape peripheral
tolerance mechanisms to drive autoimmune responses.
ACKNOWLEDGMENTS
We thank Dr. Mark Jenkins for providing the
pODpCAGGS plasmid, Drs. Diane Mathis and Christophe
Benoist for the KRN-transgenic mice and the B6.H-2g7-
congenic mice, Dr. Nilabh Shastri for providing the BWZ.36
cells, Dr. Martin Weigert for critical reading of the manuscript,
and the staff at the Transgenic Core Facility of the University
of Chicago for generating the mGPI-transgenic mice.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Huang had full access to all of the
data in the study and takes responsibility for the integrity of the data
and the accuracy of the data analysis.
Study conception and design. Perera, Huang.
Acquisition of data. Perera, Liu, Zhou, Joseph, Meng, Turner.
Analysis and interpretation of data. Perera, Liu, Joseph, Turner,
Huang.
REFERENCES
1. Goodnow CC. Multistep pathogenesis of autoimmune disease.
Cell 2007;130:25–35.
2. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learn-
ing self-control in the thymus. Nat Rev Immunol 2005;5:772–82.
3. Oehen SU, Ohashi PS, Burki K, Hengartner H, Zinkernagel RM,
Aichele P. Escape of thymocytes and mature T cells from clonal
deletion due to limiting tolerogen expression levels. Cell Immunol
1994;158:342–52.
4. Akkaraju S, Ho WY, Leong D, Canaan K, Davis MM, Goodnow
CC. A range of CD4 T cell tolerance: partial inactivation to
organ-specific antigen allows nondestructive thyroiditis or insulitis.
Immunity 1997;7:255–71.
5. Haribhai D, Engle D, Meyer M, Donermeyer D, White JM,
Williams CB. A threshold for central T cell tolerance to an in-
ducible serum protein. J Immunol 2003;170:3007–14.
6. Bogen B, Dembic Z, Weiss S. Clonal deletion of specific thymo-
cytes by an immunoglobulin idiotype. EMBO J 1993;12:357–63.
7. Pugliese A, Zeller M, Fernandez A, Zalcberg LJ, Bartlett RJ,
Ricordi C, et al. The insulin gene is transcribed in the human
thymus and transcription levels correlated with allelic variation at
the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes.
Nat Genet 1997;15:293–7.
8. Jaeckel E, Lipes MA, von Boehmer H. Recessive tolerance to
preproinsulin 2 reduces but does not abolish type 1 diabetes. Nat
Immunol 2004;5:1028–35.
9. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C,
Mathis D. Organ-specific disease provoked by systemic auto-
immunity. Cell 1996;87:811–22.
10. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA,
et al. Arthritis critically dependent on innate immune system
players. Immunity 2002;16:157–68.
11. Suri A, Vidavsky I, van der Drift K, Kanagawa O, Gross ML,
Unanue ER. In APCs, the autologous peptides selected by the
diabetogenic I-Ag7 molecule are unique and determined by the
amino acid changes in the P9 pocket. J Immunol 2002;168:
1235–43.
12. Dongre AR, Kovats S, deRoos P, McCormack AL, Nakagawa T,
Paharkova-Vatchkova V, et al. In vivo MHC class II presentation
of cytosolic proteins revealed by rapid automated tandem mass
spectrometry and functional analyses. Eur J Immunol 2001;31:
1485–94.
13. Shih FF, Mandik-Nayak L, Wipke BT, Allen PM. Massive thymic
deletion results in systemic autoimmunity through elimination of
CD4 CD25 T regulatory cells. J Exp Med 2004;199:323–35.
14. Ehst BD, Ingulli E, Jenkins MK. Development of a novel trans-
genic mouse for the study of interactions between CD4 and CD8
T cells during graft rejection. Am J Transplant 2003;3:1355–62.
15. Sanderson S, Shastri N. LacZ inducible, antigen/MHC-specific
T cell hybrids. Int Immunol 1994;6:369–76.
16. Brooks A, Hartley S, Kjer-Nielsen L, Perera J, Goodnow CC,
Basten A, et al. Class II-restricted presentation of an endoge-
nously derived immunodominant T-cell determinant of hen egg
lysozyme. Proc Natl Acad Sci U S A 1991;88:3290–4.
17. Williams CB, Vidal K, Donermeyer D, Peterson DA, White JM,
INSUFFICIENT ANTIGEN PRESENTATION IN A MOUSE MODEL OF RA 2855
Allen PM. In vivo expression of a TCR antagonist: T cells escape
central tolerance but are antagonized in the periphery. J Immunol
1998;161:128–37.
18. Graham Solomons JT, Zimmerly EM, Burns S, Krishnamurthy N,
Swan MK, Krings S, et al. The crystal structure of mouse phos-
phoglucose isomerase at 1.6Å resolution and its complex with
glucose 6-phosphate reveals the catalytic mechanism of sugar ring
opening. J Mol Biol 2004;342:847–60.
19. Huang H, Kearney JF, Grusby MJ, Benoist C, Mathis D. Induction
of tolerance in arthritogenic B cells with receptors of differing
affinity for self-antigen. Proc Natl Acad Sci U S A 2006;103:
3734–9.
20. Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of
in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol
1992;4:661–71.
21. Stockinger B. T lymphocyte tolerance: from thymic deletion to
peripheral control mechanisms. Adv Immunol 1999;71:229–65.
22. Barnes MJ, Powrie F. Regulatory T cells reinforce intestinal
homeostasis. Immunity 2009;31:401–11.
23. Suri A, Levisetti MG, Unanue ER. Do the peptide-binding
properties of diabetogenic class II molecules explain auto-
reactivity? Curr Opin Immunol 2008;20:105–10.
24. Chang KY, Suri A, Unanue ER. Predicting peptides bound to
I-Ag7 class II histocompatibility molecules using a novel expectation-
maximization alignment algorithm. Proteomics 2007;7:367–77.
25. Simons DM, Picca CC, Oh S, Perng OA, Aitken M, Erikson J,
et al. How specificity for self-peptides shapes the development and
function of regulatory T cells. J Leukoc Biol 2010;88:1099–1107.
26. Wirnsberger G, Hinterberger M, Klein L. Regulatory T-cell
differentiation versus clonal deletion of autoreactive thymocytes.
Immunol Cell Biol 2010;89:45–53.
27. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-
10-deficient mice develop chronic enterocolitis. Cell 1993;75:
263–74.
28. Mathis D, Benoist C. Back to central tolerance. Immunity 2004;
20:509–16.
29. Schwartz RH. T cell anergy. Annu Rev Immunol 2003;21:305–34.
30. Singh NJ, Schwartz RH. The strength of persistent antigenic
stimulation modulates adaptive tolerance in peripheral CD4
T cells. J Exp Med 2003;198:1107–17.
31. Eynon EE, Parker DC. Small B cells as antigen-presenting cells in
the induction of tolerance to soluble protein antigens. J Exp Med
1992;175:131–8.
32. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory
T cells. Science 1992;258:1156–9.
33. Yan J, Mamula MJ. B and T cell tolerance and autoimmunity in
autoantibody transgenic mice. Int Immunol 2002;14:963–71.
2856 PERERA ET AL
